Q&A Webinar: The Evolving NHS Landscape in England – From Policy to Practice

Pharma Market Access Insights - from Petauri Evidence

Content provided by Petauri Evidence. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Petauri Evidence or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

1M ago 1:00:10

MP3•Episode home

Send us a text

In this NHS Whispers live Q&A webinar, Katie Mulholland (Senior Consultant, UK Market Access, Petauri Evidence) speaks to:
- Sarah Everest Ford (Programme Director, Health and Care Partnership)
- Patrick McGee (Deputy Programme Director for Pathology, Lancashire & South Cumbria)
- Prof. Phil Richardson (Former Dorset ICS System Commissioning Director; now Chief Innovation Officer, Petauri Evidence)
Together, they explore the implications of changing NHS structure and policy, and what this means for your market access, stakeholder engagement, and product innovation strategies.
This episode was first broadcast as a live webinar on 19th September 2025. Some to the topics discussed may evolve over time. This session was shaped by your questions. Key themes included:
- Evolving NHS structures, policies, and practices – and what this means for industry
- Strategic commissioning: where will it happen, and who will lead it?
- The 10 Year Plan and its implications for innovation and access
- How industry can adapt to new engagement models and financial constraints
- What the shift to integrated neighbourhoods means for product rollout and service design
Learn more at: https://petauri.com/insights/evolving-nhs-landscape-policy-to-practice/
For support with navigating the evolving NHS and launching new medicines and products in England, please email [email protected].
Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Chapters

1. Intro (00:00:00)

2. Are the ICB and NHS England redundancies really going to happen, and what is driving this decision? (00:03:08)

3. What might replace NHS England, and over what time period? (00:07:01)

4. Do you think this is a real change for the better, or just a reshuffle of chairs? (00:10:01)

5. Have we identified any of the initial integrated health organisation foundation trusts, and how will their effectiveness be measured? (00:16:29)

6. How can national policy interact with and inform the current NHS restructure? (00:18:36)

7. How could a single national formulary possibly work? (00:21:08)

8. Will the move to a single national formulary be realistic within two years, or will it evolve over the 10-year plan? (00:24:00)

9. How might the process of getting onto tariff or national frameworks change? (00:25:07)

10. How do the one-, three-, and five-year budgets link into a shift to prevention? (00:26:02)

11. What potential solutions could overcome the barrier of short-term costs vs long-term benefits? (00:30:46)

12. How can the NHS and pharma work together to manage long-term conditions despite short-term budgets? (00:34:26)

13. How will the NHS adopt innovative technologies like AI without adding to the digital burden? (00:37:53)

14. How will the NHS ensure AI and clinical informatics are safely implemented without adding to the digital burden? (00:45:20)

15. Is there appetite for strategic partnerships with industry, and what kind of initiatives would add most value? (00:50:30)

16. With the devolution of specialised commissioning to ICBs, do you think they are ready to manage the increased load? (00:53:18)

17. Final thoughts: What advice would you give to help listeners navigate the changing NHS structure? (00:57:02)

71 episodes

#Science #Fitness #Biology #Business #Medicine #Mtech Access #Pharmaceutical #Pharma #Market Access #Health Economics #Heores #Medtech #NHS #Healthcare